GlassScriptPhysician profile
Andrew Williams
NPI 1346627551
$84,333.03
in general payments reported to CMS, 2019-2025
14 companies · $805 in 2025
The $805 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.70 · 2020: $139 · 2021: $546 · 2022: $331 · 2023: $76K · 2024: $6,568 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $76K · Consulting Fee: $5,250 · Food and Beverage: $1,422 · Travel and Lodging: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $75,574.50 |
| Consulting Fee | $5,250.00 |
| Food and Beverage | $1,422.39 |
| Travel and Lodging | $1,058.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $76,320.26 | 2019-2025 | Neurostar Tms Therapy System |
| Janssen Scientific Affairs, LLC | $6,387.13 | 2024 | Spravato |
| Janssen Pharmaceuticals, INC | $450.78 | 2021-2025 | Spravato |
| Alkermes, INC. | $355.93 | 2021-2023 | Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $313.20 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $160.20 | 2021-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $98.27 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $63.61 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.00 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $41.41 | 2022-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $35.66 | 2025 | Trintellix |
| Abbvie INC. | $29.87 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.33 | 2023 | Rexulti |
| Indivior INC. | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.